Mentoring Junior Faculty: Viral hepatitis Clinical Research
Mentoring Junior Faculty: Viral hepatitis Clinical Research
批准号:
8663882
负责人:
MICHAEL W FRIED
金额:
$15.33万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-07-01 至 2015-04-30
关键词:
18 year oldAdherenceAdverse eventAlanineAlternative MedicineAnti-Inflammatory AgentsAnti-inflammatoryAntioxidantsAntiviral AgentsAntiviral TherapyApoptosisAwardBiological MarkersBlood specimenChronic Hepatitis BChronic Hepatitis CChronic viral hepatitisClinicalClinical ResearchClinical TrialsComorbidityConduct Clinical TrialsCoupledDataDedicationsDevelopmentDevelopment PlansDiseaseDoseDose-LimitingDrug KineticsEnrollmentEnsureEnvironmentEvaluationFacultyFundingHepaticHepatitis BHepatitis C virusHumanImmune responseIndividualInflammationInterdisciplinary StudyInterferonsIsomerismLegalonLiver diseasesMasksMeasuresMedicalMentorsMethodologyMilk ThistleMonitorMorbidity - disease rateNational Center for Complementary and Alternative MedicineNational Institute of Diabetes and Digestive and Kidney DiseasesNormal RangeOutcomeOwnershipOxidative StressPatientsPeripheral Blood Mononuclear CellPharmaceutical PreparationsPharmacodynamicsPhasePlacebosPopulationPreparationRNARandomizedResearchResearch ActivityResearch PersonnelResearch SupportRibavirinSafetySerumSeveritiesSignal PathwaySilymarinTimeToxic effectTransferaseTranslational ResearchTreatment ProtocolsUnited States National Institutes of HealthVertebral columnViralViral hepatitisalternative treatmentdesigndiariesdosagefibrogenesisimprovedmortalitynovelnucleoside analogpatient oriented researchplacebo controlled studyprimary outcomeprogramspsychosocialresearch studyresponsescreeningsilibininsilychristinsilydianinskillssuccesstherapy developmenttreatment duration
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Chronic viral hepatitis is a major global cause of morbidity and mortality. Over the last decade, significant progress has occurred in the development of new treatments for chronic hepatitis C and hepatitis B, although management strategy of these diseases continues to evolve. More than half of patients undergoing treatment with peginterferon and ribavirin for chronic hepatitis C can achieve a sustained virological response. However, numerous patients still fail to achieve permanent viral eradication or are not candidates for initial antiviral therapy due to medical or psychosocial comorbidities which are contraindications to peginterferon and ribavirin therapy. In contrast, treatments for chronic hepatitis B with nucleoside analogues, as examples, are better tolerated, although efficacy is generally measured by prolonged viral suppression, rather than permanent cure. For both these diseases, a better understanding of mechanisms of diminished response to therapy, development of optimized treatment regimens, and/or the identification of alternative or novel medications is of critical importance. The UNC Liver Diseases Program, under the direction of Dr. Michael Fried, is extremely active in pursuing studies that focus on treatment of chronic viral hepatitis. For the purposes of this application, we will discuss an ongoing phase I/II study, funded by NCCAM/NIDDK, that investigates silymarin (milk thistle) as an alternative treatment for patients with chronic hepatitis C who failed to respond to conventional antiviral therapy (U01-AT003560, SyNCH). Furthermore, we will review a new study for chronic hepatitis B, the Hepatitis B Clinical Research Network, funded by NIDDK (U01 DK082867). Finally, we will present a detailed synopsis of an investigator initiated study that examines interferon signaling pathways in peripheral blood mononuclear cells utilizing novel methodologies. These studies provide the backbone of the mentoring program for junior faculty and fellows who are actively involved in their design, implementation, and analysis. As demonstrated within this application, mentees have been integrated into these research activities which have provided them with numerous opportunities in a mentored environment within which to develop research skills and to assert their ownership of individual projects.
期刊论文(30)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1002/hep.26641
发表时间:
2013-12
期刊:
HEPATOLOGY
影响因子:
13.5
作者:
[Fried, Michael W., Buti, Maria, Dore, Gregory J., Flisiak, Robert, Ferenci, Peter, Jacobson, Ira, Marcellin, Patrick, Manns, Michael, Nikitin, Igor, Poordad, Fred, Sherman, Morris, Zeuzem, Stefan, Scott, Jane, Gilles, Leen, Lenz, Oliver, Peeters, Monika, Sekar, Vanitha, De Smedt, Goedele, Beumont-Mauviel, Maria]
通讯作者:
Beumont-Mauviel, Maria
DOI:
10.1056/nejmoa1014463
发表时间:
2011-09-15
期刊:
The New England journal of medicine
影响因子:
--
作者:
[Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F, ILLUMINATE Study Team]
通讯作者:
ILLUMINATE Study Team
DOI:
10.1037/a0029030
发表时间:
2013-04-01
期刊:
JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY
影响因子:
5.9
作者:
[Evon, Donna M., Golin, Carol E., Keefe, Francis J.]
通讯作者:
Keefe, Francis J.
Hepatitis C infection with normal liver chemistry tests.
肝脏化学检查正常的丙型肝炎感染。
DOI:
10.1016/j.cgh.2008.02.040
发表时间:
2008
期刊:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
影响因子:
--
作者:
[Fried,MichaelW]
通讯作者:
Fried,MichaelW
Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.
Ledipasvir 和 Sofosbuvir(联合或不联合利巴韦林)在经历过治疗的基因 1 型丙型肝炎病毒感染和肝硬化患者中的安全性和有效性。
DOI:
10.1016/j.cgh.2017.12.037
发表时间:
2018
期刊:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
影响因子:
--
作者:
[Lim,JosephK, Liapakis,AnnMarie, Shiffman,MitchellL, Lok,AnnaS, Zeuzem,Stefan, Terrault,NorahA, Park,JamesS, Landis,CharlesS, Hassan,Mohamed, Gallant,Joel, Kuo,Alexander, Pockros,PaulJ, Vainorius,Monika, Akushevich,Lucy, Michael,Larr]
通讯作者:
Michael,Larr
共 17 条
The North Carolina Hepatitis Beta Clinical Research Network
-
批准号:7932806
-
项目类别:
-
资助金额:$32.05万
-
财政年份:2008
-
负责人:MICHAEL W FRIED
-
依托单位:
The North Carolina Hepatitis Beta Clinical Research Network
-
批准号:8545812
-
项目类别:
-
资助金额:$34.96万
-
财政年份:2008
-
负责人:MICHAEL W FRIED
-
依托单位:
North Carolina Hepatitis B Research Network
-
批准号:9352985
-
项目类别:
-
资助金额:$6.36万
-
财政年份:2008
-
负责人:MICHAEL W FRIED
-
依托单位:
The North Carolina Hepatitis Beta Clinical Research Network
-
批准号:7578384
-
项目类别:
-
资助金额:$14.91万
-
财政年份:2008
-
负责人:MICHAEL W FRIED
-
依托单位:
The North Carolina Hepatitis Beta Clinical Research Network
-
批准号:8330280
-
项目类别:
-
资助金额:$37.2万
-
财政年份:2008
-
负责人:MICHAEL W FRIED
-
依托单位:
The North Carolina Hepatitis Beta Clinical Research Network
-
批准号:8139899
-
项目类别:
-
资助金额:$22.02万
-
财政年份:2008
-
负责人:MICHAEL W FRIED
-
依托单位:
DIVISION OF DIGESTIVE DISEASES SERUM AND TISSUE BANK
-
批准号:7716753
-
项目类别:
-
资助金额:$0.02万
-
财政年份:2008
-
负责人:MICHAEL W FRIED
-
依托单位:
The North Carolina Hepatitis Beta Clinical Research Network
-
批准号:8728819
-
项目类别:
-
资助金额:$14.41万
-
财政年份:2008
-
负责人:MICHAEL W FRIED
-
依托单位:
The North Carolina Hepatitis Beta Clinical Research Network
-
批准号:7693739
-
项目类别:
-
资助金额:$41.59万
-
财政年份:2008
-
负责人:MICHAEL W FRIED
-
依托单位:
A phase I/II randomized, placebo controlled trial of silymarin for hepatitis C
-
批准号:7123141
-
项目类别:
-
资助金额:$14.94万
-
财政年份:2006
-
负责人:MICHAEL W FRIED
-
依托单位:
A phase I/II randomized, placebo controlled trial of silymarin for hepatitis C
-
批准号:7497799
-
项目类别:
-
资助金额:$4.25万
-
财政年份:2006
-
负责人:MICHAEL W FRIED
-
依托单位:
A phase I/II randomized, placebo controlled trial of silymarin for hepatitis C
-
批准号:7275247
-
项目类别:
-
资助金额:$28.72万
-
财政年份:2006
-
负责人:MICHAEL W FRIED
-
依托单位:
A phase I/II randomized, placebo controlled trial of silymarin for hepatitis C
-
批准号:7480368
-
项目类别:
-
资助金额:$34.46万
-
财政年份:2006
-
负责人:MICHAEL W FRIED
-
依托单位:
PEGASYS PLUS AMANTADINE AND PEGASYS PLUS AMANTADINE PLUS RIBAVIRIN
-
批准号:7377403
-
项目类别:
-
资助金额:$0.02万
-
财政年份:2005
-
负责人:MICHAEL W FRIED
-
依托单位:
VIRAHEP-C: A STUDY OF ANTIVIRAL RESISTANCE IN AFR AMER/CAUCASIAN-HEP C
-
批准号:7377429
-
项目类别:
-
资助金额:$1.34万
-
财政年份:2005
-
负责人:MICHAEL W FRIED
-
依托单位:
Mentoring Junior Faculty: Hepatitis C Clinical Research
-
批准号:6712400
-
项目类别:
-
资助金额:$13.93万
-
财政年份:2004
-
负责人:MICHAEL W FRIED
-
依托单位:
Mentoring Junior Faculty: Hepatitis C Clinical Research
-
批准号:7452374
-
项目类别:
-
资助金额:$13.93万
-
财政年份:2004
-
负责人:MICHAEL W FRIED
-
依托单位:
INTERFERON RESISTANCE IN AFRICAN-AMERICANS
-
批准号:7200198
-
项目类别:
-
资助金额:$0.09万
-
财政年份:2004
-
负责人:MICHAEL W FRIED
-
依托单位:
Mentoring Junior Faculty: Hepatitis C Clinical Research
-
批准号:6881617
-
项目类别:
-
资助金额:$13.93万
-
财政年份:2004
-
负责人:MICHAEL W FRIED
-
依托单位:
VIRAHEP-C: A STUDY OF ANTIVIRAL RESISTANCE IN AFR AMER/CAUCASIAN-HEP C
-
批准号:7200229
-
项目类别:
-
资助金额:$13.57万
-
财政年份:2004
-
负责人:MICHAEL W FRIED
-
依托单位:
海外基金